Psychedelic Business Spotlight – July 1
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!
Author: James Hallifax
MindMed Reassures Investors over Nasdaq Delisting Fears
In a Reddit AMA, MindMed CEO Robert Barrow says Nasdaq delisting is not “a risk of any sort.”
Colorado to Legalize Psychedelics?
A Colorado initiative gives voters the power to legalize psychedelics and psilocybin therapy this November.
This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
DMT is Effective at Treating Depression, New Study Finds
DMT is a powerful hallucinogen that can conjure visions of entities and alien worlds, but new research shows it can also treat depression.
Psychedelic Business Spotlight – June 17
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.
Psychedelic Business Spotlight – June 10
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
The History of LSD: A Story of Self-Experimentation
Despite the LSD experience lasting only two hours, Hofmann was amazed at the power of his creation. And like any good scientist, he knew exactly what he had to do: self-experiment.
End of content
End of content